RxDoctor Payments Data

Sharron Carr

Nurse Practitioner · Gainesville, FLNPI 1982744025

Payments from drug & device makers

$5,269in general payments, 2019–2025

Across 303 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$785
  • AbbVie$433
  • Boehringer Ingelheim$402
  • Biohaven Pharmaceuticals, Inc.$274
  • AstraZeneca$222
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,269100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,269 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$2,773
Medicare patients
43
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban13$19,699
JanuviaSitagliptin Phosphate14$15,721
RybelsusSemaglutide13$15,711
FarxigaDapagliflozin Propanediol14$14,574
Levothyroxine Sodium73$843
Atorvastatin Calcium79$664
Amlodipine Besylate80$548
Omeprazole35$504
Metoprolol Succinate33$459
Albuterol Sulfate HfaAlbuterol Sulfate18$440
Rosuvastatin Calcium35$396
Potassium Chloride17$376
Lisinopril64$366
Gabapentin11$281
Losartan Potassium41$264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$196$19,69913 claims
MerckJanuvia$118$15,72114 claims
Novo NordiskRybelsus$1,513$15,71113 claims
AstraZenecaFarxiga$222$14,57414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →